



Eli Lilly and Co / LLY

Equity | Generated Aug 28, 2026 11:31 PM EDT

Current price	Daily move	Bid / Ask	Previous close
\$1,172.50	-3.60 -0.31%	-/-	\$1,176.10

Market	NYSE
Industry	Pharmaceuticals
Market data as of	Aug 28, 2026 11:31 PM EDT

JW Intelligence Report

Complete | 3 of 3 sections | Aug 28, 2026 7:51 PM EDT

JW Rank	Rank label	Confidence	IV percentile
60.8 / 100	Balanced	high	16 / 100

Model reference	Upside scenario	Risk reference	Wheel strategy fit
\$1,165.00	\$1,235.00	\$1,125.00	67 / 100

Options stance	bullish
Tail-risk safety	56 / 100
JW Rank data coverage / as of	100.0% Aug 28, 2026 7:51 PM EDT

Key insight

LLY Option Market Implies Continued Upside Potential

Market read

The option market for LLY suggests a bullish outlook despite recent price pullback. While short-term volatility is present, the overall term structure and skew indicate continued upside potential driven by strong fundamentals and pipeline advancements.

Strategy context

LLY's recent pullback from its August high presents an opportunity for investors seeking long-term upside.




JW AI conclusions

Short- and medium-term model interpretation

AI context bias	Bullish
AI analysis updated	Aug 28, 2026 1:43 PM EDT
Short-term scenario	
Cautious buy/accumulation on support test (1-3 weeks); wait for bounce confirmation above \$1,180. High uncertainty from recent ATH fade, mixed oscillators, and valuation. Not financial advice.	
Three-month outlook	
Constructive/bullish with 8-15% upside potential toward \$1,260-1,350 (analysts consensus ~\$1,315, some \$1,400). Driven by GLP-1 volume (Mounjaro/Zepbound/Foundayo), retatrutide data, manufacturing expansion, and pipeline (Alzheimer's, oncology, oral incretins). Raised 2026 guidance supports. Key uncertainties: premium valuation (P/E ~40) vs growth sustainability, intensifying NVO/competition/pricing pressure, regulatory/reimbursement (Medicare), black-market risks, and broader market/macro. Execution on next-gen assets critical; pullback could extend if momentum fades.	
Market sentiment	
Mixed-to-cautiously positive amid pullback. Recent posts highlight FDA Mounjaro CV expansion as a win broadening value; efforts vs counterfeit GLP-1s. Some profit-taking/selling cited (e.g., retatrutide peptides/black market concerns); others note institutional accumulation on dip, strong sales momentum, and Darvas box setup. Valuation gravity and NVO competition mentioned as risks. Overall tape suggests dip-buying interest with structural GLP-1 optimism.	
Supporting evidence	
Implied volatility (IV) remains elevated at 30%, suggesting expectations for continued price movement. The term structure shows a slight upward slope, with longer-dated options trading at higher IV than near-term options, indicating belief in sustained growth. The delta 25 skew is balanced, meaning there's no significant preference for calls or puts, reflecting a neutral view on directionality but still pricing in potential movement.	
Risk watch	
Valuation remains high at a forward P/E of ~28.8, making the stock susceptible to profit-taking if growth expectations are not met.	

Enhanced price structure


45 trading days with volume, model levels and current technical reference bands



45 complete trading-session observations

JW Rank factors

Score, source coverage and interpretation for each decision factor



Decision summary

Primary model reads before the detailed indicator appendix

Momentum

bullish_recovery

Institutional flow

Below MVWAP

Structure

Above 200D trend

Volatility

medium

Decision indicators

Detailed momentum, institutional and structural observations

Momentum kinematics

Direction, velocity and oscillator state

Current read	BULLISH RECOVERY neutral MACD decelerating
Trend signal	BULLISH RECOVERY
RSI signal	neutral
RSI (7 / 14 / 21)	36.34 / 45.45 / 48.67
RSI velocity	-3.27
MACD line / signal / histogram	7.39 / - / 13.91
MACD acceleration	-4.37
Stochastic K / D	13.41 / 30.38

Institutional footprints

Volume-weighted cost, price location and flow

Current read	Below institutional MVWAP Accumulation bias
Institutional flow	0.95
20-day MVWAP	\$1,199.95
Price vs 20-day MVWAP	-2.29%
Daily reference VWAP	\$1,172.51
Price vs daily reference	0.00%
Volume	1.19M

Structural context

Long-term trend and volatility boundaries

Current read	Above 200-day trend Positive macro velocity
Macro velocity	0.44
20-day / 200-day SMA	\$1,202.53 / \$1,059.78
Bollinger range	\$1,118.46 - \$1,286.61
Bollinger position	0.334

Options and volatility intelligence

Structure, premium conditions and principal risks

IV rank

18 / 100

IV percentile

16 / 100

VVIX

87.10


SKEW

144.05

Market regime	Calm
Tail-risk regime	NORMAL TAIL RISK
Term structure	flat
Term slope	+1.17 pts
Skew read	balanced
Liquidity / quote coverage	100.0%
Options observation	Aug 28, 2026 4:41 PM EDT Coverage 77.8%

Option term structure

ATM implied-volatility curve by days to expiration



EXPIRATION	DTE	ATM IV	STATE
2026-09-04	7	29.5%	-
2026-09-11	14	29.1%	-
2026-09-18	21	30.7%	-

Event and tail-risk context

Known event windows and broad volatility conditions

Next earnings date	2026-10-29
Earnings IV-crush risk	NOT MEASURED
VIX	14.60
VVIX	87.10
SKEW index	144.05
Observation confidence	medium
Option quote quality	reliable
Contracts observed	100
Contracts with quotes	100

Strategy fit

Generalized structure fit; not a personalized recommendation

Market structure

The option market for LLY suggests a bullish outlook despite recent price pullback. While short-term volatility is present, the overall term structure and skew indicate continued upside potential driven by strong fundamentals and pipeline advancements.

Options context

LLY Option Market Implies Continued Upside Potential

Wheel context

LLY's recent pullback from its August high presents an opportunity for investors seeking long-term upside.

Observed evidence

Implied volatility (IV) remains elevated at 30%, suggesting expectations for continued price movement. | The term structure shows a slight upward slope, with longer-dated options trading at higher IV than near-term options, indicating belief in sustained growth. | The delta 25 skew is balanced, meaning there's no significant preference for calls or puts, reflecting a neutral view on directionality but still pricing in potential movement.

Principal risks to monitor

Valuation remains high at a forward P/E of ~28.8, making the stock susceptible to profit-taking if growth expectations are not met.

Fundamentals and events

Business quality, valuation and upcoming event context

Market capitalization	P/E (TTM)
\$1.10T	43.17
ROE	Revenue growth
92.6%	31.7%
EPS growth	Operating margin
49.3%	42.2%
Net profit margin	Gross margin
33.5%	-
Free cash flow CAGR	Debt / equity
5.9%	1.60
Dividend yield	Beta
0.8%	0.45
52-week range	
\$712.05 - \$1,292.65	

Company or fund profile

Issuer identity and classification

Name	Market
Eli Lilly and Co	NYSE
Industry	Country
Pharmaceuticals	US
Currency	IPO date
USD	1970-07-09
Shares outstanding	52-week return
941.74M	60.2%
Book value per share	Revenue per share
\$35.98	\$89.14
Website	lilly.com



Latest strategy observation

Most recent shared general market signal available when this report was generated

LLY Covered Call signal	Aug 28, 2026 10:26 AM EDT
Covered Call 2026-09-11	
At signal \$1,173.50 Current \$1,172.50	
SHORT Option \$1,175.00 B \$24.65 / A \$27.80	
High turnover CR \$26.23	

Complete technical details

Full supporting indicator set used by the symbol detail experience

Volatility and options market

Price movement and premium conditions

ATR	\$38.46
ATR as % of price	3.3%
Volatility environment	medium
Current IV	30.2%
IV rank	19 / 100
IV percentile	16 / 100

Technical health and risk radar

Derived indicator health and event context

Overall health	77 / 100
Trend health	78 / 100
Momentum health	83 / 100
Volatility health	61 / 100
Structure health	83 / 100
Earnings risk / date	low 2026-10-29
Macro risk	unknown
Volatility risk	medium
Structure risk	low

Structural indicator levels

Moving averages, volatility bands and observed trading ranges

SMA (20 / 50 / 200)	\$1,202.53 / \$1,186.84 / \$1,059.78
EMA (9 / 21)	\$1,206.17 / \$1,203.87
Bollinger upper / middle / lower	\$1,286.61 / \$1,202.53 / \$1,118.46
Bollinger %B	0.334
True high / low	\$1,180.00 / \$1,162.93

Structural indicator levels (continued)

Moving averages, volatility bands and observed trading ranges

FIELD	VALUE
5-day true high / low	\$1,264.73 / \$1,162.93

Three-day indicator history

Short-horizon change and the underlying three-session observations

INDICATOR	3-DAY CHANGE	SESSION 1 / 2 / 3
SMA20	0.438	-
SMA50	1.175	-
MVWAP20	0.948	-
MACD	-4.366	-
RSI	-3.272	-
Volume	-11037.670	-
ATR	-0.746	-
T1	-	11.34 / 1197.87 / 1190.11 / 1171.71
T2	-	16.06 / 1196.77 / 1235.78 / 1180.01
T3	-	20.49 / 1197.11 / 1264.73 / 1229.79

Detailed options evidence

Supporting option-chain, execution and data-quality observations

Underlying price at observation	\$1,164.35
Options intelligence as of	Aug 28, 2026 4:41 PM EDT
Options data coverage	77.8%
SKEW regime	HIGH TAIL RISK SKEW
VVIX regime	VVIX FLAT
Front expiration / DTE	2026-09-04 7 DTE
Front at-the-money IV	29.5%
25-delta skew	0.48
Put / Call 25-delta	\$1,135.00 Delta -0.257 / \$1,195.00 Delta 0.276
Median option bid/ask spread	20.0%
Bid/ask spread	-
Contracts observed / quoted	100 / 100

Price context

Last Price: 1,164.35 | Bid: 1,164.15 | Ask: 1,164.57 | Previous Close: 1,176.10 | Change: -11.75 |
 Daily change: -1.00% | Update Time: 2026-08-28T14:43:22.264066-04:00 | Latest History Date: 2026-08-28
 | Latest History Price: 1,164.34

Historical context

Trading-day sample: 60 sessions | First Date: 2026-06-04 | Latest Date: 2026-08-28 | Latest Price:
 1,164.34 | Max Drawdown 60d Percent: -9.70%

Fundamental context

Current Iv Percent: 30.03% | Iv Rank: 18.48 | Iv Percentile: 15.54 | Next Earnings Date: 2026-10-29 |
 Ex Dividend Date: 2026-08-13 | Dividend Yield: 59.00

Important disclosures

Scope, limitations, risk and permitted interpretation

General market information only

This report is general quantitative research and market commentary. It is not investment, legal, tax or accounting advice; it is not an offer, solicitation, order, recommendation or promise of performance. It does not consider any reader's holdings, objectives, financial circumstances, risk tolerance or suitability.

Model observations - not instructions

JW Rank, strategy fit, model reference, upside scenario and risk reference levels are model observations. They are not entries, price targets, stops, position sizes or instructions to buy, sell, open, close or hold a security or option. A higher score does not imply lower risk or a guaranteed favorable outcome.

Data, AI and model limitations

Prices, volumes, fundamentals, options data, news-derived context and model outputs reflect the timestamps shown and may be delayed, incomplete, revised or inaccurate. AI-generated explanations can omit context or produce errors. Models can fail when volatility, liquidity, correlations or market regimes change.

Performance and scenario limitations

Past, hypothetical, back-tested, simulated and model-derived results are not indicative of future results. Strategy statistics may exclude commissions, fees, taxes, slippage, early assignment, execution constraints and other costs unless expressly stated. Actual outcomes may differ materially.

Options risk

Options are complex and are not suitable for all investors. They may involve total or substantial loss, assignment, early exercise, margin calls, liquidity and spread risk, volatility and Greek exposure, event risk, regime shifts and expiration risk. Multi-leg positions may not execute or close at modeled prices.

Investor responsibility and ODD

Use current market information, assess suitability independently and consult qualified professionals when appropriate. Before trading listed options, read Characteristics and Risks of Standardized Options (ODD) available from the Options Clearing Corporation at theocc.com.

Generated Aug 28, 2026 11:31 PM EDT. Jason Wheel Terms of Use and Privacy Policy apply. Copyright Jason Wheel Research LLC. All rights reserved.

Reference documents

Official product terms and standardized options disclosure

Jason Wheel	jasonwheel.com
Terms of Use	jasonwheel.com / Terms
Privacy Policy	jasonwheel.com / Privacy
Options Disclosure Document	theocc.com / Options Disclosure Document